This week in Infectious Disease

Nov 20, 2026

Latest episode · 11 min
Editor’s pick

Seasonal mass vaccination with R21/Matrix-M against malaria in The Gambia and Burkina Faso: an open-label, cluster-randomised, controlled trial.

Whole-population seasonal R21/Matrix-M vaccination across 54 villages cut odds of malaria infection by 70 percent in The Gambia and 25 percent in Burkina Faso, with good safety.

The Lancet · 2026 · PubMed

This week’s highlights

  1. 01Assessing Multiple Treatment Regimens for Tuberculosis.

    In a phase 2 trial of 401 adults with drug-susceptible tuberculosis, two 16-week regimens containing ganfeborole or BTZ-043 showed promising culture kinetics and acceptable safety for phase 3 testing.

    Esmail H, Paton NI, Schildkraut JA, et al. · New England Journal of Medicine · 2026

    PMID 43056221

  2. 02Seasonal mass vaccination with R21/Matrix-M against malaria in The Gambia and Burkina Faso: an open-label, cluster-randomised, controlled trial.

    Whole-population seasonal R21/Matrix-M vaccination across 54 villages cut odds of malaria infection by 70 percent in The Gambia and 25 percent in Burkina Faso, with good safety.

    Dabira ED, Natama HM, Erhart A, et al. · The Lancet · 2026

    PMID 43057277

  3. 03Acute kidney injury and death in severe Plasmodium falciparum malaria: An individual patient data meta-analysis.

    Pooled data from over 16,000 severe malaria patients support a urea threshold of 10 mmol/L or age-based creatinine thresholds, identifying four to eight times more high-risk children.

    Watson JA, Conroy AL, Batte A, et al. · PLOS Medicine · 2026

    PMID 43056420

  4. 04Prevalence and Outcomes of Primary Bedaquiline Resistance in Adults With Rifampicin-Resistant Pulmonary Tuberculosis.

    In Western Cape, South Africa, over half of baseline bedaquiline resistance in rifampicin-resistant tuberculosis was primary, and outcomes were poor, worse with acquired than primary resistance.

    Beckwith PG, Brust JCM, Meintjes G, et al. · Open Forum Infectious Diseases · 2026

    PMID 43041638

  5. 05Mortality and prognostic factors in invasive aspergillosis: a systematic review and individual patient data meta-analysis.

    Across 3,880 patients, invasive aspergillosis mortality was about 27 percent at four weeks and over half at one year, highest in ICU patients and cerebral disease, with high heterogeneity.

    Kimura Y, Tanimura K, Inoue N, et al. · The Lancet Infectious Diseases · 2026

    PMID 43057280

  6. 06A Multicenter Interventional Trial Using Blood Mucorales Polymerase Chain Reaction as a Screening Tool in High-Risk Hematology Patients (MUCOPS).

    Twice-weekly plasma Mucorales PCR screening in 200 high-risk haematology patients was feasible, detected occult mucormycosis, and had a negative predictive value of 99.9 percent.

    Vanbiervliet Y, Aerts R, Boon E, et al. · Open Forum Infectious Diseases · 2026

    PMID 43061072

  7. 07Revised Consensus Clinical Trial Response Criteria by the Mycoses Study Group Education & Research Consortium and European Confederation of Medical Mycology.

    An international expert panel updated the 2008 antifungal trial response criteria for mould infections, invasive candidiasis, cryptococcosis and dimorphic fungi in adults and children.

    Hoenigl M, Thompson GR, Pappas PG, et al. · Clinical Infectious Diseases · 2026

    PMID 43043133

  8. 08Improving the treatment of invasive fungal infections: novel antifungal and host-directed therapies.

    A narrative review describes first-in-class antifungals, combination and local antifungal strategies, and host-directed immune therapies advancing through development for invasive fungal infections.

    Feys S, Sprute R, Dellière S, et al. · The Lancet Infectious Diseases · 2026

    PMID 43051211

  9. 09Surviving sepsis guideline suggesting Selective digestive decontamination is unsafe.

    A commentary argues the 2026 Surviving Sepsis suggestion for selective digestive decontamination relies on older trials whose apparent benefit may reflect spillover effects, absent in recent cluster trials.

    Hurley JC · Journal of Antimicrobial Chemotherapy · 2026

    PMID 43058059

  10. 10Pilot Randomized Trial of Patient-Directed vs Fixed-Antibiotic Duration in Acute Pyelonephritis.

    In a double-blind pilot trial in women with pyelonephritis, stopping antibiotics after symptom resolution gave similar clinical resolution and adverse events to fixed duration, supporting a larger trial.

    Faine B, Moran G, Krishnadasan A, et al. · Open Forum Infectious Diseases · 2026

    PMID 43041632

Read the weekly briefing

This AudioScholar briefing is generated by artificial intelligence from PubMed abstracts for healthcare professionals and is not medical advice.

This week: two new four-drug regimens advance in tuberculosis, seasonal mass vaccination against malaria cuts infection across whole villages, and malaria kidney injury thresholds are redrawn for children.

Welcome to This Week in Infectious Disease. We're covering 10 papers this week: 3 in depth, 4 in brief, 3 quick signals.

In the New England Journal of Medicine, Esmail and colleagues report PARADIGM4TB, a phase 2 randomized trial in 401 adults with rifampin-susceptible pulmonary tuberculosis [1]. The abstract does not name the trial sites. Participants received standard isoniazid, rifampin, pyrazinamide and ethambutol for 24 weeks, bedaquiline, delamanid and moxifloxacin for 16 weeks, or one of ten new four-drug combinations for 16 weeks built around two new agents, ganfeborole and BTZ-043. The primary end point was how fast time to sputum culture positivity lengthened over the first 12 weeks, judged as the Bayesian probability of beating standard therapy. Two regimens were selected for further study. BTZ-043 with bedaquiline, delamanid and moxifloxacin improved that slope by about a fifth, with a 99 percent probability of superiority. Ganfeborole with bedaquiline, pretomanid and moxifloxacin improved it by about nine percent, with an 83 percent probability. Severe adverse events occurred in 38 percent of patients on the ganfeborole regimen, 28 percent on the BTZ-043 regimen and 24 percent on standard therapy, and one BTZ-043 arm containing pyrazinamide was stopped for liver toxicity. The main limitation is the surrogate end point, which the authors used for regimen selection rather than to show efficacy, and the abstract reports no cure or relapse data. The trial adds a shortlist of four-month candidates for phase 3 testing.

In The Lancet, Dabira and colleagues report an open-label cluster-randomised trial of seasonal mass vaccination with the R21/Matrix-M malaria vaccine in 54 villages in The Gambia, with low-to-moderate seasonal transmission, and Burkina Faso, with intense transmission [2]. All residents aged 5 months and older in intervention villages were offered three monthly doses before peak transmission, on top of standard national malaria control. Roughly 60 percent of residents in the Gambian villages and about 65 percent in the Burkinabe villages received all three doses. The primary outcome was Plasmodium falciparum infection by PCR at peak season. Vaccination cut the odds of infection by 70 percent in The Gambia and by 25 percent in Burkina Faso, both statistically significant. In The Gambia prevalence fell across all age groups, whereas in Burkina Faso the largest effect was in children under five. Of 69 serious adverse events, only one was judged vaccine-related, a febrile convulsion in an eight-year-old. Limitations include the open-label design, a single cross-sectional survey and an infection end point rather than clinical malaria, over one season. The trial is the first randomized evidence that whole-population seasonal R21 vaccination reduces infection, with a much larger effect where transmission is lower.

Also on malaria, Watson and colleagues in PLOS Medicine pooled individual data from 14 studies of severe falciparum malaria, with 16,441 patients in the primary analysis, of whom 84 percent were children under 15 [3]. Current kidney injury thresholds for severe malaria are based on adult creatinine values and ignore the lower muscle mass of children. Using day 28 mortality, the authors found that an admission creatinine more than three times the age and weight predicted baseline was associated with mortality above five percent. A urea above 10 millimoles per litre carried similar prognostic value. In children, urea predicted death better than creatinine and, unlike creatinine, tracked parasite biomass measured by plasma PfHRP2. The authors propose either a urea threshold of 10 millimoles per litre for all ages or simple age-based creatinine thresholds, and estimate these would identify four to eight times more children with high-risk kidney injury. The main limitations are missing details on laboratory methods and wide variation in study eligibility criteria. The analysis adds a large evidence base for redefining severe malaria kidney injury in children, though the proposed thresholds are not yet in guidelines.

Now, four in brief.

Back to tuberculosis. In Open Forum Infectious Diseases, Beckwith and colleagues describe a retrospective cohort from the Western Cape, South Africa, of 146 patients with rifampicin-resistant tuberculosis and bedaquiline resistance detected at baseline [4]. Just over half of these patients, 81 in total, had primary resistance with no prior bedaquiline exposure, pointing to transmission. Resistance to other second-line drugs was common, except linezolid. Of 80 patients with an outcome, 28 died. Acquired resistance was linked to slower culture conversion and far fewer favourable outcomes than primary resistance, about one in eight versus just under half. This is a retrospective single-province study, and it bears on the bedaquiline-based regimens in the tuberculosis trial above.

Turning to fungal disease, Kimura and colleagues in The Lancet Infectious Diseases report an individual patient data meta-analysis of invasive aspergillosis, drawing on 46 studies and 3,880 patients [5]. Estimated all-cause mortality was about 27 percent at four weeks and just over half at one year. ICU mortality was about 57 percent, and four-week mortality was highest in ICU patients and in brain disease, at around 40 percent for cerebral aspergillosis. COVID-19 predominated in the ICU cohort. Heterogeneity across cohorts was very high, and individual data came from fewer than a quarter of eligible studies, so these figures are best read as broad contemporary estimates.

Also in Open Forum Infectious Diseases, the MUCOPS study by Vanbiervliet and colleagues tested twice-weekly plasma Mucorales PCR screening in 200 Belgian adults undergoing induction for acute myeloid leukaemia or myelodysplastic syndrome, or first allogeneic transplant [6]. Across 2,400 tests, screening uncovered five otherwise occult mucormycosis cases, three by plasma PCR and two by lavage PCR only. Plasma PCR sensitivity was about 83 percent and negative predictive value 99.9 percent, while positive predictive value was about half. Positive results led to liposomal amphotericin B within about a day. With only a handful of cases and no comparison arm, survival benefit is not established.

In Clinical Infectious Diseases, Hoenigl and colleagues present revised consensus response criteria for antifungal clinical trials from the Mycoses Study Group Education and Research Consortium and the European Confederation of Medical Mycology, replacing the 2008 criteria [7]. The update covers aspergillosis and other mould diseases, invasive candidiasis, cryptococcosis and dimorphic fungi in adults and children. This is expert consensus, and its main effect will be on how future antifungal trials, including those of new agents, define success.

Three quick signals.

Feys and colleagues in The Lancet Infectious Diseases review the antifungal pipeline, including first-in-class agents, combination and local antifungal therapy, and host-directed immune approaches [8]. It is a narrative review and adds no new trial data, but it maps the agents that the revised trial criteria will be applied to.

In the Journal of Antimicrobial Chemotherapy, Hurley argues that the 2026 Surviving Sepsis suggestion to use selective digestive decontamination in ventilated adults rests on older trials with unusually high pneumonia rates in concurrent controls, a benefit not seen in recent cluster trials [9]. This is a single-author commentary raising spillover as an alternative explanation, not new data.

In Open Forum Infectious Diseases, Faine and colleagues report a double-blind multicentre pilot trial in women with pyelonephritis, finding that stopping antibiotics based on symptom resolution gave similar sustained clinical resolution and adverse events to a fixed course [10]. As a pilot, it shows feasibility and does not establish efficacy or safety.

Stepping back across this week's papers, much of the evidence rests on intermediate measures rather than hard clinical outcomes: culture kinetics in place of cure and relapse, infection prevalence in place of clinical disease, and diagnostic accuracy in place of survival. The larger pooled analyses describe risk well but carry wide heterogeneity, and several contributions are consensus statements, commentaries or pilots. The randomized evidence that exists is mostly early-phase or open-label, so confirmation in later trials remains the gap.

If you only have time for one paper this week, make it the seasonal mass vaccination trial with R21 [2]. It is the first randomized test of vaccinating whole communities against malaria, and it reopens the question of where vaccines fit in elimination strategies beyond young children.

That's your roundup for This Week in Infectious Disease. The full transcript and references are available on the episode page. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And think of one colleague, in any specialty, who never has time to keep up with the literature. Tell them about AudioScholar: a ten-minute weekly for every specialty, to listen to in any podcast app, or to read at audioscholar dot C C.

This is an automated summary generated by artificial intelligence, which can make mistakes. Use it to choose which papers to read in full.

Get Infectious Disease every week

By email, Spotify, Apple or any podcast app.

Listen on Apple PodcastsListen on Spotify

Spot something worth flagging?